BLOOMS THE CHEMIST METFORMIN XR 1000 metformin hydrochloride 1000 mg modified release tablet blister pack Australija - anglų - Department of Health (Therapeutic Goods Administration)

blooms the chemist metformin xr 1000 metformin hydrochloride 1000 mg modified release tablet blister pack

gm pharma international pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: povidone; colloidal anhydrous silica; hypromellose; magnesium stearate - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

PLASMA-LYTE 148 (approx. pH 7.4) 1000mL injection bag AHB2544 Australija - anglų - Department of Health (Therapeutic Goods Administration)

plasma-lyte 148 (approx. ph 7.4) 1000ml injection bag ahb2544

baxter healthcare pty ltd - sodium acetate, quantity: 3.68 g/l; potassium chloride, quantity: 370 mg/l; magnesium chloride hexahydrate, quantity: 300 mg/l; sodium gluconate, quantity: 5.02 g/l; sodium chloride, quantity: 5.26 g/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections - plasma-lyte 148 (approx. ph 7.4) iv infusion is indicated as a source of water and electrolytes or as an alkalinising agent.

PLASMA-LYTE 148 (approx. pH 7.4) 500mL injection bag AHB2543 Australija - anglų - Department of Health (Therapeutic Goods Administration)

plasma-lyte 148 (approx. ph 7.4) 500ml injection bag ahb2543

baxter healthcare pty ltd - sodium gluconate, quantity: 5.02 g/l; sodium acetate, quantity: 3.68 g/l; sodium chloride, quantity: 5.26 g/l; magnesium chloride hexahydrate, quantity: 300 mg/l; potassium chloride, quantity: 370 mg/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections - plasma-lyte 148 (approx. ph 7.4) iv infusion is indicated as a source of water and electrolytes or as an alkalinising agent.

JARDIAMET 12.5 mg / 1000 mg empagliflozin/metformin hydrochloride 12.5mg/1000mg film coated tablet blister pack Australija - anglų - Department of Health (Therapeutic Goods Administration)

jardiamet 12.5 mg / 1000 mg empagliflozin/metformin hydrochloride 12.5mg/1000mg film coated tablet blister pack

boehringer ingelheim pty ltd - empagliflozin, quantity: 12.5 mg; metformin hydrochloride, quantity: 1000 mg - tablet, film coated - excipient ingredients: maize starch; copovidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide red; iron oxide black; macrogol 400 - jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin is appropriate (see sections 4.2 dose and method of administration and 5.1 pharmacodynamic properties - clinical trials).,empagliflozin is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease to reduce the risk of cardiovascular death (see section 5.1 pharmacodynamic properties - clinical trials).,to prevent cardiovascular deaths, empagliflozin should be used in conjunction with other measures to reduce cardiovascular risk in line with the current standard of care.

JARDIAMET 12.5 mg / 850 mg empagliflozin/metformin hydrochloride 12.5mg/850mg film coated tablet blister pack Australija - anglų - Department of Health (Therapeutic Goods Administration)

jardiamet 12.5 mg / 850 mg empagliflozin/metformin hydrochloride 12.5mg/850mg film coated tablet blister pack

boehringer ingelheim pty ltd - empagliflozin, quantity: 12.5 mg; metformin hydrochloride, quantity: 850 mg - tablet, film coated - excipient ingredients: maize starch; copovidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide red; iron oxide black; macrogol 400 - jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin is appropriate (see sections 4.2 dose and method of administration and 5.1 pharmacodynamic properties - clinical trials).,empagliflozin is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease to reduce the risk of cardiovascular death (see section 5.1 pharmacodynamic properties - clinical trials).,to prevent cardiovascular deaths, empagliflozin should be used in conjunction with other measures to reduce cardiovascular risk in line with the current standard of care.

JARDIAMET 12.5 mg / 500 mg empagliflozin/metformin hydrochloride 12.5mg/500mg film coated tablet blister pack Australija - anglų - Department of Health (Therapeutic Goods Administration)

jardiamet 12.5 mg / 500 mg empagliflozin/metformin hydrochloride 12.5mg/500mg film coated tablet blister pack

boehringer ingelheim pty ltd - empagliflozin, quantity: 12.5 mg; metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: maize starch; copovidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide red; iron oxide black; macrogol 400 - jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin is appropriate (see sections 4.2 dose and method of administration and 5.1 pharmacodynamic properties - clinical trials).,empagliflozin is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease to reduce the risk of cardiovascular death (see section 5.1 pharmacodynamic properties - clinical trials).,to prevent cardiovascular deaths, empagliflozin should be used in conjunction with other measures to reduce cardiovascular risk in line with the current standard of care.

JARDIAMET  5 mg / 1000 mg empagliflozin/metformin hydrochloride 5mg/1000mg film coated tablet blister pack Australija - anglų - Department of Health (Therapeutic Goods Administration)

jardiamet 5 mg / 1000 mg empagliflozin/metformin hydrochloride 5mg/1000mg film coated tablet blister pack

boehringer ingelheim pty ltd - empagliflozin, quantity: 5 mg; metformin hydrochloride, quantity: 1000 mg - tablet, film coated - excipient ingredients: maize starch; copovidone; colloidal anhydrous silica; magnesium stearate; hypromellose; purified talc; iron oxide yellow; macrogol 400 - jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin is appropriate (see sections 4.2 dose and method of administration and 5.1 pharmacodynamic properties - clinical trials).,empagliflozin is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease to reduce the risk of cardiovascular death (see section 5.1 pharmacodynamic properties - clinical trials).,to prevent cardiovascular deaths, empagliflozin should be used in conjunction with other measures to reduce cardiovascular risk in line with the current standard of care.

JARDIAMET 5 mg / 850 mg empagliflozin/metformin hydrochloride 5mg/850mg film coated tablet blister pack Australija - anglų - Department of Health (Therapeutic Goods Administration)

jardiamet 5 mg / 850 mg empagliflozin/metformin hydrochloride 5mg/850mg film coated tablet blister pack

boehringer ingelheim pty ltd - empagliflozin, quantity: 5 mg; metformin hydrochloride, quantity: 850 mg - tablet, film coated - excipient ingredients: maize starch; copovidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 400 - jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin is appropriate (see sections 4.2 dose and method of administration and 5.1 pharmacodynamic properties - clinical trials).,empagliflozin is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease to reduce the risk of cardiovascular death (see section 5.1 pharmacodynamic properties - clinical trials).,to prevent cardiovascular deaths, empagliflozin should be used in conjunction with other measures to reduce cardiovascular risk in line with the current standard of care.

JARDIAMET 5 mg / 500 mg empagliflozin/metformin hydrochloride 5mg/500mg film coated tablet blister pack Australija - anglų - Department of Health (Therapeutic Goods Administration)

jardiamet 5 mg / 500 mg empagliflozin/metformin hydrochloride 5mg/500mg film coated tablet blister pack

boehringer ingelheim pty ltd - empagliflozin, quantity: 5 mg; metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: maize starch; copovidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 400 - jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin is appropriate (see sections 4.2 dose and method of administration and 5.1 pharmacodynamic properties - clinical trials).,empagliflozin is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease to reduce the risk of cardiovascular death (see section 5.1 pharmacodynamic properties - clinical trials).,to prevent cardiovascular deaths, empagliflozin should be used in conjunction with other measures to reduce cardiovascular risk in line with the current standard of care.

DIAFORMIN XR 1000 metformin hydrochloride 1000mg extended release tablet blister pack. Australija - anglų - Department of Health (Therapeutic Goods Administration)

diaformin xr 1000 metformin hydrochloride 1000mg extended release tablet blister pack.

alphapharm pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: hypromellose; magnesium stearate; carmellose sodium - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. diaformin xr and diaformin xr 1000 may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.